in Nucleic Acid Therapeutics for Human Health


  • HOME
  • R & D
  • OliX Pipeline
  • OLX101A


  • Is a result of overgrowth of collagen in the dermis,
    wound-repair frequently results in scar formation
    in extreme cases-hypertrophic scars or keloids
  • No universal standard of care and no approved drugs for the
    reduction of scarring
  • Scar prevention or reduction is a therapeutic area of
    unmet medical need


Market Potential

  • The global hypertrophic & keloid scar treatment market size has been projected to reach about $ 4.3 B based on year 2016.
    (source from Grand View Research 2017)


  • Target gene - Connect Tissue Growth Factor (CTGF)

Development Status

  • Efficient inhibition of fibrosis identified in animal models
  • Technology transferred to Hugel within Asia (Nov. 1, 2013)
  • Thesis published(preclinical trial) in Journal of Investigate Dermatology
  • First in Asia to complete phase 1 clinical trial of RNA interference drug (May 16, 2018), obtain approval for phase 2 clinical trial (executed by Hugel on Nov. 7, 2018)
  • Completion of phase 1 clinical trial in UK (Nov. 2019)
  • Expects to submit an IND for a Phase 2 clinical trial in USA

Government Funding

Other Applications of OLX101

└ Applicable to a variety of diseases caused by excessive fibrosis, such as Idiopathic Pulmonary Fibrosis


  • Hwang, J., Chang, C., Kim, J. H., Oh, C. T., Lee, H. N., Lee, C., Oh, D., Lee, C., Kim, B., Hong, S. W., & Lee, D. K. (2016). Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. Journal of Investigative Dermatology, 136(11), 2305-2313.